
    
      A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa
      (Recombinant) in Congenital Hemophilia A or B Pediatric Patients from birth to <12 years old
      with Inhibitors to Factor VIII or IX: PerSept 2
    
  